Positive Effect of Methylphenidate for Cancer-Related Cognitive Impairment: A Pilot Randomized Trial.
Jessica Boivin, Anne Dagnault, Maman Joyce Dogba et al.
✦ AI-curated · Sources linked
In 30 seconds
This pilot randomized, double-blind, placebo-controlled trial assessed methylphenidate (MPH) for cancer-related cognitive impairment in women who had completed breast cancer treatment at least six months earlier and had documented cognitive dysfunction. Twenty participants were randomized to MPH or placebo, with all completing the study. By Day 29, the MPH group showed greater improvement in self-reported perceived cognitive impairment than the placebo group (mean difference = 10.1, P = 0.02). Neuropsychological test scores did not differ between groups. Reported side effects were mild to moderate and transient.
Key findings
- At Day 29, FACT-Cog Perceived Cognitive Impairments scores improved more with MPH than placebo (mean difference = 10.1, P = 0.02).
- No between-group differences were observed in neuropsychological test scores.
- All 20 participants completed the trial; self-reported MPH side effects were mild to moderate and transient.
- MPH did not worsen physical, psychological, or sleep-related symptoms compared with placebo.
Why it matters
Cognitive symptoms can persist after breast cancer treatment, and this pilot trial suggests MPH may improve patients’ perceived cognitive difficulties. The difference in self-reported outcomes, alongside no observed worsening of other symptoms, supports further study. However, the absence of improvement on neuropsychological tests means the findings do not establish a broader objective cognitive benefit.
What to keep in mind
This was a small pilot trial with 20 participants and short follow-up through Day 29. Self-reported cognitive improvement was not accompanied by between-group differences on neuropsychological tests.